Somewhat Favorable News Coverage Somewhat Unlikely to Affect Tobira Development (TBRA) Share Price

Media stories about Tobira Development (NASDAQ:TBRA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tobira Development earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.193012339994 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Tobira Development (NASDAQ TBRA) remained flat at $$42.09 on Friday. The company has a current ratio of 5.38, a quick ratio of 5.38 and a debt-to-equity ratio of 0.44. Tobira Development has a 1 year low of $3.76 and a 1 year high of $42.33.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Tobira Development (TBRA) Share Price” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.com-unik.info/2017/12/23/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-tobira-development-tbra-share-price.html.

Tobira Development Company Profile

Tobira Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The Company’s product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5) in late stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure.

Insider Buying and Selling by Quarter for Tobira Development (NASDAQ:TBRA)

Receive News & Ratings for Tobira Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Development and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit